secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001558370-24-014522
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Therapeutics reports Q3 net loss $7.6M, improved from $29.3M YoY; cash into 2028
--------------------------------------------------------------------------------

- Net loss of $7.6M vs $29.3M in Q3 2023; revenue fell to $4.3M from $9.3M.
- R&D expenses dropped to $6.0M from $23.9M, driven by reduced clinical and manufacturing costs.
- Cash, equivalents and marketable securities of $173.4M expected to fund operations into 2028.
- First patient dosed in Phase 2a trial of ATI-2138 for atopic dermatitis; top-line data expected H1 2025.
- Seeking global development partner for lepzacitinib (ATI-1777) after positive Phase 2b in atopic dermatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024014522/0001558370-24-014522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837024014522/acrs-20241106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer